Verax Biomedical, Incorporated products

Verax’s patented Pan Genera Detection (PGD) technology is based on the insight that recent advances in the field of immunotherapeutic agents can be used to develop tests to detect the broad array of bacteria in blood components. This broad detection is based on the existence of shared, or conserved, antigens that are common to the cell walls of the two broad classes of bacteria – Lipoteichoic Acids on Gram-positive bacteria and Lipopolysaccharides on Gram-negative bacteria. Verax targets these conserved Gram-positive and Gram-negative antigens to test biological samples for a broad range of bacterial contaminants by using pan genera binding agents to directly bind to these targets. This detection approach does not depend upon surrogate measures for bacterial presence or the measurement of byproducts of bacterial growth.